  Targeted anticancer therapies have significantly increased the survival of patients with a variety of malignancies , improving tolerability and treatment duration. The increased lifespan and the expanded use of targeted agents have led to a variety of treatment-related adverse events. Pruritus , a common dermatologic adverse event with various incidences ranging from 2.2 % to 47 % across different categories of targeted anticancer therapies , has been overlooked. This article reviews the incidence , accompanying skin conditions , possible pathomechanism , and proposed management algorithms of pruritus associated with targeted therapies , including immunotherapies.